The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a ...

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a ...

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

Companies that have broken ground or begun construction on US manufacturing sites will be exempt from these tariffs.

Eli Lilly halted a study on bimagrumab for Type 2 diabetes patients, focusing on weight loss and muscle mass preservation.

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...

A new report from Reuters 1 details how the residents of Kalundborg, Denmark, are reacting to the news of the looming layoffs ...

Glenmark partners with Hengrui Pharma to develop Trastuzumab Rezetecan, enhancing its oncology pipeline and addressing unmet ...

Harmony Biosciences reveals disappointing results from the Phase III Reconnect study of ZYN002 for Fragile X Syndrome, ...

In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the ...

Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims ...

Investors may not be convinced about the danger of Tylenol.